Design Therapeutics (DSGN) Cash & Current Investments (2020 - 2026)

Design Therapeutics has disclosed Cash & Current Investments across 7 years of filings, most recently posting $222.8 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $222.8 million, down 2.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $222.8 million (down 2.98% YoY), and the FY2025 annual result was $219.8 million, down 10.44% from the prior year.
• Cash & Current Investments came in at $222.8 million for Q1 2026 at Design Therapeutics, up from $219.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $371.2 million in Q1 2022 to a low of $206.0 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $270.7 million (2024), against an average of $277.8 million.
• Across the five-year window, Cash & Current Investments retreated 18.93% in 2025 and retreated 2.98% in 2026, its largest moves.
• Design Therapeutics' Cash & Current Investments stood at $330.4 million in 2022, then slipped by 14.71% to $281.8 million in 2023, then dropped by 12.89% to $245.5 million in 2024, then declined by 10.44% to $219.8 million in 2025, then advanced by 1.35% to $222.8 million in 2026.
• The last three Cash & Current Investments figures came in at $222.8 million (Q1 2026), $219.8 million (Q4 2025), and $206.0 million (Q3 2025), per Business Quant data.